Zenabis Global (TSX:ZENA) is the latest marijuana company to strengthen its play in the cannabis-infused beverages ring.
Less than two months out from the legalization of edible and infused cannabis products in Canada, the BC-based company has signed an agreement with an undisclosed Canadian beverage technology company. This partner will supply Zenabis with plain water-soluble cannabis-infused inputs.
The announcement, sent out after trading hours on Monday (August 26), confirms that the company plans to develop its own drinks with an onset time of less than five minutes. Onset time refers to how long it takes for a beverage to affect the user.
In an interview with the Investing News Network (INN), Andrew Grieve, CEO of Zenabis, said the decision to move towards cannabis-infused beverages was designed as a way to challenge the alcohol market’s dominance in the recreational beverage space.
“Alcohol has had a monopoly on the recreational experience in the market for an incredibly long period of time,” Grieve told INN. “As a result, people have not had an alternative.”
He added that he thinks the highly controlled physical effects of cannabis drinks will make them more attractive than their alcoholic counterparts.
“I believe that, if you have a beverage technology with a known onset and offset and limited calories and the flavor profile that people want, people will choose a cannabis infused-beverage for their recreational experience over an alcoholic beverage,” he told INN.
The company plans on both recreational and wellness drink lines.
Grieve didn’t give any details about the beverage technology company Zenabis is working with, but did say its name will be released once the products are available to consumers.
As part of the announcement, Grieve confirmed these beverages will launch in Canada following the legalization of edibles and infused products.
The executive said his company’s drinks will be infused without any effect on taste or smell. In his view, this is a benefit compared to competitors planning to launch their own beverages.
Grieve cited a report from Deloitte, which estimates that the next round of cannabis legalization could create a C$2.7 billion market in Canada, with beverages contributing a significant part of yearly profits.
Zenabis has experienced a small swing upward since shares opened on Tuesday (August 27) at C$1.07. The company closed the day at C$1.05, representing a 2.94 percent jump for the day.
Zenabis will use the beverage inputs to produce a variety of tetrahydrocannabinol- (THC) and cannabidiol- (CBD) infused drinks, ensuring that it adheres to the rules on these products, which are set to come into effect on October 17. Federal legislation limits the amount of THC in food and drinks to 10 milligrams of THC per package.
“It is expected that a limited selection of products will appear gradually in physical or online stores, and no earlier than mid-December 2019,” Health Canada said.
One product Zenabis already has in the works is a CBD-infused kombucha line to be created with True Büch, a cultured tea beverage maker in which Zenabis acquired a 51 percent stake earlier this year.
Various players in the Canadian marijuana industry have expressed interest in the launch of infused beverages. Additionally, a selection of established beverage makers have signed partnerships with cannabis companies to lend expertise on the development of these drinks.
Among others, Zenabis is joining the likes of Dixie Brands (CSE:DIXI.U,OTCQX:DXBRF) in the cannabis beverage arena. The Colorado-based cannabis company announced a partnership with drink maker AriZona to create a line of THC-infused drinks this month.
HeavenlyRx, a CBD wellness company, has also moved into the cannabis beverage space with an investment in craft pop maker Jones Soda (OTCQB:JSDA). It plans to create a Jones-branded line of CBD-infused drinks.
In its results for Q2 2019, Zenabis reported cultivating over 2,400 kilograms of dried cannabis, exceeding its forecast by 40 percent. The report also notes an increase in annual production capacity at its facility in Atholville, New Brunswick, to 46,300 kilograms up from 34,300 kilograms.
Grieve told INN that the company also plans on rolling out edible cannabis-infused products, including gummies and chocolates, and hopes that both its cannabis food and beverages will hit shelves by December or the first quarter of 2020.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.